Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

For more information, click below.


Subscribers log in here


Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth

INTRODUCTION

Autosomal dominant polycystic kidney disease (ADPKD) is a common disorder, occurring in approximately 1 in every 400 to 1000 live births [1,2]. It is estimated that less than one-half of these cases will be diagnosed during the patient's lifetime, as the disease is often clinically silent [1].

The genetics of ADPKD and the mechanisms of cyst growth will be reviewed here. Issues related to diagnosis and screening and of autosomal recessive polycystic kidney disease, which is a disease of children, are discussed separately. (See "Diagnosis of and screening for autosomal dominant polycystic kidney disease" and "Autosomal recessive polycystic kidney disease in children".)

GENETICS

A variety of genetic defects have been described, including frameshift, deletion and missense mutations in patients with ADPKD. Most families have an abnormality on chromosome 16 in the PKD1 locus that is tightly linked to the alpha-globin gene locus [3-6]. Most of the remaining patients have a defect in the PKD2 locus on chromosome 4 [7-9]. A few families have a defect unrelated to either locus [10-12].

Initial studies suggested that PKD1 was responsible for 96 percent of cases [3,4]. Subsequent data suggest that, at least in Europe, the incidence is lower at about 86 percent [7]. Macroscopic cysts occur later in PKD2 disease as does end-stage renal disease (mean age 74 versus 54 years in PKD1) [13]. As a result, false negative results are more likely when screening young subjects with this disorder (see below).

PKD gene products — The genes for both PKD1 and PKD2 have been identified [14-17]. PKD1 and PKD2 encode proteins called polycystin-1 and polycystin-2, respectively [14-18]. PKD1 is an extremely large and complex gene (46 exons) that generates a 14 kb mRNA, encoding a protein of over 4000 amino acids in length; PKD2 is smaller (15 exons) and encodes a protein a little smaller than 1000 amino acids in length [17].

           

Subscribers log in here

To continue reading this article you must have access through your hospital or your group practice, log in to your personal subscription, or purchase a personal subscription. For more information, click below.
Literature review current through: Apr 2013. | This topic last updated: May 20, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2013 UpToDate, Inc.
References
Top
  1. Davies F, Coles GA, Harper PS, et al. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991; 79:477.
  2. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332.
  3. Parfrey PS, Bear JC, Morgan J, et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323:1085.
  4. Breuning MH, Reeders ST, Brunner H, et al. Improved early diagnosis of adult polycystic kidney disease with flanking DNA markers. Lancet 1987; 2:1359.
  5. Arnaout MA. The vasculopathy of autosomal dominant polycystic kidney disease: insights from animal models. Kidney Int 2000; 58:2599.
  6. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13:2384.
  7. Peters DJ, Spruit L, Saris JJ, et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 1993; 5:359.
  8. Pei Y, He N, Wang K, et al. A spectrum of mutations in the polycystic kidney disease-2 (PKD2) gene from eight Canadian kindreds. J Am Soc Nephrol 1998; 9:1853.
  9. Torra R, Viribay M, Tellería D, et al. Seven novel mutations of the PKD2 gene in families with autosomal dominant polycystic kidney disease. Kidney Int 1999; 56:28.
  10. Daoust MC, Reynolds DM, Bichet DG, Somlo S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics 1995; 25:733.
  11. de Almeida E, Martins Prata M, de Almeida S, Lavinha J. Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3. Nephrol Dial Transplant 1999; 14:631.
  12. Reed B, McFann K, Kimberling WJ, et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis 2008; 52:1042.
  13. Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353:103.
  14. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994; 77:881.
  15. Gardner KD Jr, Glew RH, Evan AP, et al. Why renal cysts grow. Am J Physiol 1994; 266:F353.
  16. Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272:1339.
  17. Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005; 67:1234.
  18. Wilson PD. Polycystin: new aspects of structure, function, and regulation. J Am Soc Nephrol 2001; 12:834.
  19. Geng L, Segal Y, Peissel B, et al. Identification and localization of polycystin, the PKD1 gene product. J Clin Invest 1996; 98:2674.
  20. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995; 81:289.
  21. Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, et al. Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci U S A 1997; 94:6397.
  22. Huan Y, van Adelsberg J. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest 1999; 104:1459.
  23. Carone FA, Nakamura S, Bacallao R, et al. Impaired tubulogenesis of cyst-derived cells from autosomal dominant polycystic kidneys. Kidney Int 1995; 47:861.
  24. Le NH, van der Wal A, van der Bent P, et al. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005; 16:2724.
  25. Piontek K, Menezes LF, Garcia-Gonzalez MA, et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 2007; 13:1490.
  26. Kim E, Walz G. Sensitive cilia set up the kidney. Nat Med 2007; 13:1409.
  27. Hanaoka K, Qian F, Boletta A, et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 2000; 408:990.
  28. Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10:363.
  29. Foggensteiner L, Bevan AP, Thomas R, et al. Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 gene. J Am Soc Nephrol 2000; 11:814.
  30. Chauvet V, Qian F, Boute N, et al. Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 2002; 160:973.
  31. Cai Y, Maeda Y, Cedzich A, et al. Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 1999; 274:28557.
  32. Murcia NS, Sweeney WE Jr, Avner ED. New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 1999; 55:1187.
  33. Bhunia AK, Piontek K, Boletta A, et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002; 109:157.
  34. Qian F, Germino FJ, Cai Y, et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 1997; 16:179.
  35. Chauvet V, Tian X, Husson H, et al. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 2004; 114:1433.
  36. Nomura H, Turco AE, Pei Y, et al. Identification of PKDL, a novel polycystic kidney disease 2-like gene whose murine homologue is deleted in mice with kidney and retinal defects. J Biol Chem 1998; 273:25967.
  37. Chen XZ, Vassilev PM, Basora N, et al. Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature 1999; 401:383.
  38. Basora N, Nomura H, Berger UV, et al. Tissue and cellular localization of a novel polycystic kidney disease-like gene product, polycystin-L. J Am Soc Nephrol 2002; 13:293.
  39. Grantham JJ. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances. Am J Kidney Dis 1996; 28:788.
  40. Qian F, Watnick TJ, Onuchic LF, Germino GG. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996; 87:979.
  41. Brasier JL, Henske EP. Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest 1997; 99:194.
  42. Lu W, Peissel B, Babakhanlou H, et al. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 1997; 17:179.
  43. Pei Y, Watnick T, He N, et al. Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999; 10:1524.
  44. Wu G, Markowitz GS, Li L, et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 2000; 24:75.
  45. Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350:151.
  46. Ye M, Grant M, Sharma M, et al. Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol 1992; 3:984.
  47. Woo DD, Miao SY, Pelayo JC, Woolf AS. Taxol inhibits progression of congenital polycystic kidney disease. Nature 1994; 368:750.
  48. Boca M, Distefano G, Qian F, et al. Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J Am Soc Nephrol 2006; 17:637.
  49. Carone FA, Nakamura S, Caputo M, et al. Cell polarity in human renal cystic disease. Lab Invest 1994; 70:648.
  50. Avner ED, Sweeney WE Jr, Nelson WJ. Abnormal sodium pump distribution during renal tubulogenesis in congenital murine polycystic kidney disease. Proc Natl Acad Sci U S A 1992; 89:7447.
  51. Grantham JJ, Ye M, Gattone VH 2nd, Sullivan LP. In vitro fluid secretion by epithelium from polycystic kidneys. J Clin Invest 1995; 95:195.
  52. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003; 64:1157.
  53. Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66:964.
  54. Torres VE. Type II calcimimetics and polycystic kidney disease: unanswered questions. J Am Soc Nephrol 2009; 20:1421.
  55. Nagao S, Nishii K, Yoshihara D, et al. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 2008; 73:269.
  56. Leuenroth SJ, Bencivenga N, Igarashi P, et al. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 2008; 19:1659.
  57. Gattone VH 2nd, Chen NX, Sinders RM, et al. Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol 2009; 20:1527.
  58. Wang X, Harris PC, Somlo S, et al. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrol Dial Transplant 2009; 24:526.
  59. Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17:118.
  60. Torres VE, Boletta A, Chapman A, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010; 5:1312.
  61. Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010; 21:489.
  62. Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012; 23:842.
  63. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33:129.
  64. Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004; 15:2528.
  65. Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens 2009; 18:99.
  66. Harris PC. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol 2009; 20:1188.
  67. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002; 13:2508.
  68. Gallagher AR, Hoffmann S, Brown N, et al. A truncated polycystin-2 protein causes polycystic kidney disease and retinal degeneration in transgenic rats. J Am Soc Nephrol 2006; 17:2719.
  69. Joly D, Hummel A, Ruello A, Knebelmann B. Ciliary function of polycystins: a new model for cystogenesis. Nephrol Dial Transplant 2003; 18:1689.
  70. Ansley SJ, Badano JL, Blacque OE, et al. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature 2003; 425:628.
  71. Li JB, Gerdes JM, Haycraft CJ, et al. Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. Cell 2004; 117:541.
  72. Herrera GA. C-erb B-2 amplification in cystic renal disease. Kidney Int 1991; 40:509.
  73. Arnould, T, Kim E, Gruning, W, et al. Cellular activation triggered by PKD2 (abstract). J Am Soc Nephrol 1998; 9:370A.
  74. Li KJ, Shiau AL, Chiou YY, et al. Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease. Kidney Int 2005; 67:1710.
  75. Gattone VH 2nd. Prothymosin alpha as a cystogen. Kidney Int 2005; 67:2063.
  76. Luyten A, Su X, Gondela S, et al. Aberrant regulation of planar cell polarity in polycystic kidney disease. J Am Soc Nephrol 2010; 21:1521.
  77. Patel V. Balancing the Wnts in polycystic kidney disease. J Am Soc Nephrol 2010; 21:1412.
  78. Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 2001; 60:37.
  79. Wei W, Popov V, Walocha JA, et al. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 2006; 70:1261.
  80. Nichols MT, Gidey E, Matzakos T, et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 2004; 40:836.
  81. McGrath-Morrow S, Cho C, Molls R, et al. VEGF receptor 2 blockade leads to renal cyst formation in mice. Kidney Int 2006; 69:1741.
  82. Gardner KD Jr, Burnside JS, Skipper BJ, et al. On the probability that kidneys are different in autosomal dominant polycystic disease. Kidney Int 1992; 42:1199.
  83. Davidow CJ, Maser RL, Rome LA, et al. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996; 50:208.
  84. Grantham JJ, Ye M, Davidow C, et al. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 6:1242.
  85. Hanaoka K, Devuyst O, Schwiebert EM, et al. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 1996; 270:C389.
  86. O'Sullivan DA, Torres VE, Gabow PA, et al. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32:976.
  87. Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11:1179.
  88. Yang B, Sonawane ND, Zhao D, et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19:1300.
  89. Nakanishi K, Sweeney WE Jr, Macrae Dell K, et al. Role of CFTR in autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2001; 12:719.